Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 1/20 | 0.38 |
| ▸ | MPL | P40238 | 2/20 | 0.37 |
| ▸ | ITGB2 | P05107 | 4/20 | 0.37 |
| ▸ | ICAM1 | P05362 | 4/20 | 0.37 |
| ▸ | ITGAL | P20701 | 4/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19951406 | 1.00 | IDH2 (0.38) | IDH2MPLITGB2ICAM1ITGAL | |
| SCHEMBL19951415 | 1.00 | IDH2 (0.38) | IDH2MPLITGB2ICAM1ITGAL | |
| SCHEMBL29464381 | 1.00 | IDH2 (0.38) | IDH2MPLITGB2ICAM1ITGAL | |
| SCHEMBL29464444 | 1.00 | IDH2 (0.38) | IDH2MPLITGB2ICAM1ITGAL | |
| SCHEMBL29464420 | 0.90 | IDH2 (0.39) | IDH2MPLITGB2ICAM1ITGAL | |
| SCHEMBL19951391 | 0.90 | IDH2 (0.39) | IDH2MPLITGB2ICAM1ITGAL | |
| SCHEMBL19925047 | 0.90 | IDH2 (0.39) | IDH2MPLITGB2ICAM1ITGAL | |
| SCHEMBL29464498 | 0.90 | IDH2 (0.39) | IDH2MPLITGB2ICAM1ITGAL | |
| SCHEMBL29464387 | 0.89 | ITGB2 (0.38) | IDH2MPLITGB2ICAM1ITGAL | |
| SCHEMBL29464328 | 0.89 | ITGB2 (0.38) | IDH2MPLITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109641873-B | N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use for the treatment of disease | 诺华股份有限公司 | 2022-03-18 | — | — | CN | claimed |
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | claimed |
| CN-109641873-B | N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use for the treatment of disease | 诺华股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2019-10-22 | — | — | US | disclosed |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2019-10-22 | — | — | US | disclosed |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | IDH2 658/4885MPL 560/4885ITGB2 2257/4885 |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | CFTR, P2RY1, P2RX5 | IDH2 658/4885MPL 560/4885ITGB2 2257/4885 |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | IDH2 658/4885MPL 560/4885ITGB2 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.